Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Stopped Trial terminated because of lack of efficacy in the short term acute phase
Conditions
Interventions
- DRUG: Ulocuplumab
- DRUG: Nivolumab
Sponsor
Bristol-Myers Squibb